Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

Social media use among older adults shows potential benefits for reducing loneliness and improving psychosocial well-being, though results vary across studies.

Proposed budget cuts threaten mental health services, risking patient care and community stability while exacerbating existing disparities in access to treatment.

FDA reviewers raise concerns over Rexulti's efficacy for PTSD, highlighting discordant study results ahead of the advisory committee meeting.

Rebecca Barbee, PA-C, CAQ-Psych, shares insights ahead of the the FDA meeting discussing brexpiprazole for PTSD.

Explore the profound impact of grandparent-grandchild relationships on well-being, connection, and legacy in this insightful reflection.

The climate crisis has worsened... What can psychiatry do to help?

The FDA advisory committee will review brexpiprazole for PTSD treatment, which could offer new hope after years without new options.

The FDA has updated ADHD stimulant labels, highlighting weight loss risks in children under 6. Stephen Mateka, DO, shares his updated treatment strategies.

"He slaps a chest film on the light box and hooks a bleary intern: Tell me, doctor, what is the shape of this child’s ears?"

Panelists discuss how 17-year-old patients challenges with inattention, anxiety, and executive dysfunction ahead of college highlight the importance of balancing pharmacologic and non-pharmacologic ADHD treatments while addressing concerns about stimulant use and medication diversion.

Panelists discuss how treatment adherence in ADHD patients is often impacted by forgetfulness and misconceptions, and how using tools like pill organizers can significantly improve consistency and outcomes.

A groundbreaking study reveals that reduced cortical thickness in the parahippocampus may indicate major depressive disorder and neuroticism traits.

Borderline personality disorder represents 10% to 25% of the patients who would be considered to have borderline personality organization. Explore the complexities of its stigma and effective treatment strategies.

Psychiatrists face rising challenges amid social crises, but these can be combatted through emotional awareness, resilience, and hope.

Discover innovative strategies for early diagnosis and treatment of bipolar disorder, addressing challenges and exploring promising new therapies.

A psychiatrist reflects on the recent flooding tragedy in Texas.

Jesse H. Wright, MD, PhD reflects on his groundbreaking contributions to cognitive behavior therapy and the evolution of psychiatric education over 5 decades.

Mental health professionals face disaster fatigue amid ongoing crises, struggling with emotional exhaustion and compassion fatigue while seeking effective solutions.

Panelists discuss the importance of setting realistic expectations when initiating pitolisant for narcolepsy, emphasizing consistent daily use, gradual titration, and patient-centered measures of success, while accounting for external stressors, lifestyle factors, and the need for occupational accommodations to support long-term functional outcomes.

Panelists discuss how behavioral strategies—including structured sleep routines, scheduled naps, dietary adjustments, light therapy, and cognitive behavioral support—are essential components of comprehensive narcolepsy management, reinforcing that individualized, nonpharmacologic interventions can significantly improve daily function and long-term outcomes.

Clinicians explore the potential of xanomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Dr Jonathan Meyer highlights effective VMAT 2 inhibitors for tardive dyskinesia treatment, emphasizing tailored approaches for improved patient outcomes.